Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

Theodore Pincus, MD  |  Issue: April 2013  |  April 1, 2013

Of course, observational data are affected by limitations not seen in randomized data. However, it is not possible, logistically or ethically, to maintain randomization in symptomatic patients with RA over periods longer than two years.27 Therefore, accurate knowledge concerning the safety and effectiveness of long-term treatment of RA with prednisone <5 mg/day requires observational data to complement clinical trials, as summarized below:28

The mean initial prednisone dose in 308 patients with RA treated between 1980 and 2004, analyzed in five-year periods, declined from 10.3 mg/day in 1980–1985 to 6.5 mg/day in 1985–1989, 5.1 mg/day in 1990–1994, 4.1 mg/day in 1995–1999, and 3.6 mg/day in 2000–2004 (see Figure 1a, p. 23). The proportion of patients whose initial dose was <5 mg/day increased from zero in 1980–1984 to 4% in 1985–1989, 23% in 1990–1994, 67% in 1995–1999, and 86% in 2000–2004 (see Figure 1b, p. 23). The proportion treated initially with 5 mg/day was 51%, 80%, 70%, 26%, and 10%, in the five-year periods, respectively. The proportion treated initially with >5 mg/day was 49%, 16%, 7%, 7%, and 3%, in the five-year periods, respectively (see Figure 1b, p. 23). Over this period, the proportion of patients treated with methotrexate rose from 10%, to 26%, 57%, 71%, and 78% in the respective five-year periods. (see Figure 1c, p. 23).23

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Higher mean initial prednisone doses were administered to patients with greater disease severity. In patients treated with ≥5 mg/day, the mean baseline MDHAQ physical function score was 3.5 (0–10 scale), mean pain score 6.3 (0–10 scale), and mean RAPID3 17.3 (0–30 scale) versus 2.4, 5.2, and 13.2, respectively, in patients treated initially with <5 mg/day.25

Improvement in clinical status over 12 months for MDHAQ function, pain, and RAPID3 was similar in patients with initial dose ≥5 mg/day—40%, 37%, and 38%, respectively—compared to patients with initial dose <5 mg/day, in whom improvement was 34%, 37%, and 37%, respectively.25 Therefore, the 86% of patients treated with <5 mg/day in 2000–2004 experienced benefit similar to those treated with higher doses, albeit that their clinical status was milder.5 These data reflect confounding by indication that patients with more severe disease received higher prednisone dose.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical improvement was maintained for up to eight years in most patients.25 These findings differ considerably from those in the 1980s and 1990s, when initial improvement was followed by progressive declines in clinical status after two to three years in most patients.5,29

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:GlucocorticoidsprednisoneRARheumatoid arthritis

Related Articles

    The Peripatetitc Theodore Pincus, MD

    July 1, 2007

    Tireless champion for patient self-report

    The Science of MDHAQ/RAPID3 Scores

    December 12, 2011

    Do patient self-reports provide valid data for evidence-based care in rheumatology practice?

    Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

    March 1, 2015

    Questions around prescribing steroids as bridge therapy, in long-term low dosages, or low-dose timed-release formulas, or not at all evoke controversy among rheumatologists

    Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

    December 18, 2019

    The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences